PENDING CLAIMS

1. (Amended) A liposomal topotecan unit dosage form, said unit dosage form comprising:

a lipid; and

a topotecan dosage of from about 0.01 mg/M^2/dose to about 7.5 mg/M^2/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by weight of about 0.05 to about 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

2. (Amended) The liposomal topotecan unit dosage form of claim 1, wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.

3. The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

4. The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises sphingomyelin and cholesterol in a ratio by weight of about 30:70 to about 60:40.

5. The liposomal topotecan unit dosage form of claim 1, comprising from about 1 mg/M^2/dose to about 4 mg/M^2/dose of topotecan.

6. A liposomal topotecan formulation, wherein said liposomal topotecan formulation retains greater than 50% active lactone species after 12 hours in blood circulation.

7. The liposomal topotecan formulation of claim 6, wherein said liposomal topotecan formulation retains greater than 80% active lactone species after 12 hours in blood circulation.

8. A liposomal topotecan formulation comprising topotecan, sphingomyelin, cholesterol and a divalent cation ionophore.

9. The liposomal topotecan formulation of claim 8, wherein said divalent ionophore is present in trace amounts.

10. (Amended) The liposomal topotecan formulation of claim 8, comprising a drug:lipid ratio by weight of about 0.05 to about 0.2.

11. (Amended) The liposomal topotecan formulation of claim 10, wherein said drug:lipid ratio by weight is about 0.05 to about 0.15

12. The liposomal topotecan formulation of claim 11, comprising trace amounts or greater of a divalent ionophore.

13. A method of treating a solid tumor in a human afflicted therewith, said method comprising administering to said human an effective amount of a topotecan dosage of claim 1 in a pharmaceutically acceptable carrier.

14. The method of claim 13, wherein said solid tumor is selected from the group consisting of solid tumors of the lung, mammary, colon and prostate.

15. The method of claim 13, further comprising co-administration of a treatment for neutropenia or platelet deficiency.

16. (Amended) A method of treating solid tumors in a mammal, said method comprising:

administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation having a drug:lipid ratio by weight of about 0.05 to about 0.2.

17. A method of treating solid tumors in a mammal, said method

comprising:

administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising from about 0.01 mg/M^2/dose to about 7.5 mg/M^2/dose of topotecan for an interval regime, wherein said interval regime is once a day for at least two consecutive days.

18. The method of treating solid tumors of claim 17, wherein said interval regime is at least once a week.

19. The method of treating solid tumors of claim 17, wherein said interval regime is at least once every two weeks.

20. The method of treating solid tumors of claim 17, wherein said interval regime is at least once every three weeks.

21. (Amended) The method of treating solid tumors of claim 17, wherein said liposomal topotecan formulation has a drug:lipid ratio by weight of about 0.05 to about 0.2.

22. A method of treating solid tumors in a mammal comprising

administering to an animal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising from about 0.01 to about 7.5 mg/M^2/dose of topotecan every three days.

23. (Amended) A liposomal camptothecin unit dosage form, said unit dosage form comprising a lipid, a camptothecin dosage of from about 0.015 mg/M^2/dose to about 1 mg/M^2/dose and having a drug:lipid ratio by weight of about 0.05 to about 0.2.